Back
Science

Two Studies Identify Predictors for Hepatitis B Treatment Success with Pegylated Interferon

Generated on: Last updated: 3 sources
View source

"Baseline age under 30 years and a decline in HBsAg level greater than 1 log10 IU/mL by week 24 were identified as key predictors of treatment response."

Two Major Studies Refine Predictors for Hepatitis B Treatment Success

Two separate studies published in medical journals have analyzed the effectiveness of virological markers in predicting treatment outcomes for chronic hepatitis B virus (HBV) infection, with a specific focus on therapies involving pegylated interferon (Peg-IFN).

Study 1: Peg-IFN-Based Therapy in Immune-Tolerant Patients

A pilot, open-label, prospective study investigated the efficacy of Peg-IFN-based treatment in adults with immune-tolerant (IT) chronic HBV infection. The study enrolled 286 patients aged 18-60 years.

Methodology and Groups

Patients were allocated to three distinct groups:

  • Combination group (n=103): Received Peg-IFN for 48-96 weeks plus tenofovir disoproxil fumarate (TDF) from week 12 to 96.
  • Monotherapy group (n=125): Received TDF alone.
  • Control group (n=58): Received no intervention.
Key Results at Week 96 (Intention-to-Treat Analysis)
  • No patients in the control group met predefined efficacy endpoints.
  • The combination group showed significantly higher response rates compared to the monotherapy group:
    • Virological response: 71.8% vs. 53.6% (p=0.005)
    • Hepatitis B e antigen (HBeAg) seroconversion: 15.5% vs. 1.6% (p<0.001)
    • Hepatitis B surface antigen (HBsAg) loss: 10.7% vs. 0% (p<0.001)
  • In the combination group, cumulative HBsAg loss was 5.4% at week 48 and 11.8% at week 96.
Predictors of Treatment Response

Statistical analysis identified two key predictors for seroconversion or HBsAg loss:

  • Baseline age under 30 years (odds ratio [OR] = 0.217, 95% CI: 0.048-0.976, p=0.046)
  • Decline in HBsAg level greater than 1 log10 IU/mL by week 24 (OR = 13.976, 95% CI: 2.506-77.932, p=0.003)

"Patients with greater than 1 log10 IU/mL HBsAg decline by week 24 may be candidates for extending Peg-IFN treatment to 72-96 weeks."

Conclusions

The study authors reported that response rates may be higher in IT patients under 30 years receiving Peg-IFN-based therapy compared to nucleoside analogue monotherapy. They suggested that patients with greater than 1 log10 IU/mL HBsAg decline by week 24 may be candidates for extending Peg-IFN treatment to 72-96 weeks. The study noted that in China, Peg-IFN-based therapy is not routinely used in adults during the IT phase.

The study was published in the Journal of Clinical and Translational Hepatology.

Study 2: Systematic Review of Virological Markers for Predicting Treatment Outcomes

A separate systematic review aimed to identify virological markers capable of predicting functional cure (HBsAg loss) and HBeAg loss following Peg-IFN treatment in individuals with chronic hepatitis B.

Methodology

Researchers analyzed 38 studies involving 6,179 patients. Data was retrieved from PubMed, Embase, the Cochrane Library, and Web of Science databases up to November 2023. Predictive effectiveness was evaluated using the summary receiver operating characteristic curve (AUROC).

Key Findings for Predicting Functional Cure (HBsAg Loss)
  • HBsAg decline at week 24 demonstrated the highest discriminative ability (AUROC 0.89) and sensitivity (0.88).
  • Baseline HBsAg levels showed comparable AUROC (0.86) and the highest specificity (0.79).
  • Both markers were significantly better predictors than baseline hepatitis B core-related antigen and HBV RNA (P < 0.001 for all comparisons).

"HBsAg decline at week 24 and baseline HBsAg levels are superior predictors for functional cure compared to other virological markers."

Key Findings for Predicting HBeAg Loss or Seroconversion
  • Several markers exhibited comparable predictive values (AUROC range: 0.75–0.78), including:
    • HBV RNA, HBV DNA, HBeAg levels, and HBeAg decline at week 12
    • HBV DNA and HBeAg decline at week 24
  • HBV RNA and HBeAg levels at week 24 showed optimal sensitivity (0.87).
  • HBeAg decline at week 12 had the highest specificity (0.83).
Conclusion

The review concluded that HBsAg decline at week 24 and baseline HBsAg levels are superior predictors for functional cure compared to other virological markers. For predicting HBeAg loss, on-treatment HBV RNA and HBeAg levels, along with their dynamic changes, were identified as the most reliable indicators.